Skip to main content
SpringerLink
Log in

Risk Reduction in Patients With Diabetes

  • Chapter
Type 2 Diabetes, Pre-Diabetes, and the Metabolic Syndrome

Part of the book series: Current Clinical Practice ((CCP))

Abstract

Patients with diabetes are at high risk for cardiovascular mortality, with the greatest cause being atherosclerotic vascular disease and its sequelae. Diabetic patients have a greater risk of permanent brain damage with carotid emboli, a threefold greater mortality from stroke, a poor prognosis for survival, and a twofold to fourfold greater risk of cardiovascular disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Suggested Reading

  1. (1998) Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet 352:854–862.

    Google Scholar 

  2. (2000) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355:253–259.

    Google Scholar 

  3. (2003) Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 26(Suppl 1):S5–S20.

    Google Scholar 

  4. Agarwal R. (2001) Add on angiotensin receptor blockade with maximized ACE inhibition. Kidney Int 59:2282–2289.

    PubMed  CAS  Google Scholar 

  5. Agewall S, Fagerberg B, Attvall S, et al. (1995) Carotid artery wall intima media thickness is associated with insulin mediated glucose disposal in men at high and low coronary risk. Stroke 26:956–960.

    PubMed  CAS  Google Scholar 

  6. American Diabetes Association. (1998) Consensus development conference on the diagnosis of coronary heart disease in people with diabetes. Diabetes Care 21:1551–1559.

    Article  Google Scholar 

  7. Ardaillou R. (1999) Angiotensin II receptors. J Am Soc Nephrol 10(Suppl):S30–S39.

    PubMed  CAS  Google Scholar 

  8. Aronson D, Bloomgarden Z, Rayfield EJ. (1996) Potential mechanisms promoting restenosis in diabetic patients. J Am Coll Cardiol 27:528–535.

    Article  PubMed  CAS  Google Scholar 

  9. Atkins RC. (1998) Dr. Atkins’ New Diet Revolution. New York, NY: Avon Books.

    Google Scholar 

  10. Azizi M, Linhart A, Alexander J, et al. (2000) Pilot study of controlled blockade of the renin-angiotensin system in essential hypertensive patients. J Hypertens 18:1839–1147.

    Article  Google Scholar 

  11. Bailey CJ. (1992) Biguanides and NIDDM. Diabetes Care 15:755–772.

    Article  PubMed  CAS  Google Scholar 

  12. Ben-Menachem E, Axelsen M, Johanson EH, Stagge A, Smith U. (2003) Predictors of weight loss in adults with topiramate-treated epilepsy. Obes Res 11:556–562.

    Article  PubMed  CAS  Google Scholar 

  13. Benjamin L. (2001) Glucose, VEGF-A, and diabetic complications. Am J Pathol 158: 1181–1184.

    PubMed  CAS  Google Scholar 

  14. Bjorntorp P. (2001) Heart and soul: stress and the metabolic syndrome. Scand Cardiovasc J 35:172–177.

    Article  PubMed  CAS  Google Scholar 

  15. Blumenthal M, Goldberg A, Brinkmann J. (2000) Herbal Medicine. Newton, MA: Integrative Medicine Communications.

    Google Scholar 

  16. Boden G. (2001) Pathogenesis of type 2 diabetes: insulin resistance. Endocrinol Metab Clin North Am 30:801–815

    Article  PubMed  CAS  Google Scholar 

  17. Boehm BO, Home PD, Behrend C, Kamp NM, Lindholm A. (2002) Premixed insulin aspart 30 vs. premixed human insulin 70/30 twice daily: a randomized trial in type 1 and type 2 diabetic patients. Diabet Med 19:393–399.

    Article  PubMed  CAS  Google Scholar 

  18. Bonow RO. (2003) Diet, obesity and cardiovascular risk. N Engl J Med 348:2082–2090.

    Article  Google Scholar 

  19. Bristol Myers Squibb Company. (July 2000) Glucovance (glyburide and metformin HCL tablets) package insert. Princeton, NJ.

    Google Scholar 

  20. Brownlee M, Cerami A, Vlassara H. (1988) Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318:1315–1321.

    Article  PubMed  CAS  Google Scholar 

  21. Buse J. (2000) Combining insulin and oral agents. Am J Med 108(Suppl 6a):23S–32S.

    Article  PubMed  CAS  Google Scholar 

  22. Carrozza J, Kuntz R, Fishman RF, Baim DS. (1993) Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus. Ann Intern Med 118:344–349.

    PubMed  Google Scholar 

  23. Carswell Cl, Plosker GL, Jarvis B. (2002) Rosuvastatin. Drugs 62:2075–2085.

    Article  PubMed  CAS  Google Scholar 

  24. Carvalho CR, Thirone AC, Gontijo JA, Velloso L, Saad MJ. (1997) Effect of captopril, losartan and bradykinin on early steps of insulin action. Diabetes 46:1950–1957.

    Article  PubMed  CAS  Google Scholar 

  25. Castelli WP. (1988) Cholesterol and lipids in the risk of coronary artery disease—the Framingham Heart Study. Can J Cardiol 4(Suppl A):5A–10A.

    PubMed  Google Scholar 

  26. Castelli, WP. (1983) Cardiovascular disease and multifactorial risk: challenge of the 1980’s. Am Heart J 106:1191–1200.

    Article  PubMed  CAS  Google Scholar 

  27. Cefalu WT, Skyler JS, Kourides IA, et al. (2001) Inhaled human insulin treatment in patients with type 2 diabetes mellitus. Ann Intern Med 134:203–207.

    PubMed  CAS  Google Scholar 

  28. Chaturvedi N, Sjolle AK, Stephenson JM, et al. (1998) Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 351:28–31.

    Article  PubMed  CAS  Google Scholar 

  29. Chiasson JL, Josse RG, Gomis R, et al. (2002) Acarbose for prevention of type 2 diabetes mellitus. The STOP-NIDDM randomized trial. Lancet 359:2072–2077.

    Article  PubMed  CAS  Google Scholar 

  30. Christensen PK, Gall MA, Parving HH. (2000) Course of glomerular filtration rate in albuminuric type 2 diabetic patients with or without diabetic glomerulopathy. Diabetes Care 23(Suppl 2):B4–B20.

    Google Scholar 

  31. Clark RS, English M, McNeill GP, Newton RW. (1985) Effect of intravenous infusion of insulin in diabetics with acute myocardial infarction. BMJ 291:303–305.

    PubMed  CAS  Google Scholar 

  32. Cohn JN, Tognoni Gianni. (2001) A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345:1667–1675.

    Article  PubMed  CAS  Google Scholar 

  33. Colwell JA. (2001) Treatment for the procoagulant state in type 2 diabetes. Endocrinol Metab Clin North Am 30:1011–1030.

    Article  PubMed  CAS  Google Scholar 

  34. Cooper M, Johnston C. (2000) Optimizing treatment of hypertension in patients with diabetes. JAMA 283:3177–3179.

    Article  PubMed  CAS  Google Scholar 

  35. Cooper ME. (1998) Pathogenesis, prevention and treatment of diabetic nephropathy. Lancet 352:213–219.

    Article  PubMed  CAS  Google Scholar 

  36. DeFronzo R, et al. (1995) Efficacy of metformin in patients with NIDDM. N Engl J Med 333:541–549.

    Article  PubMed  CAS  Google Scholar 

  37. Desai J, Geiss L, Muktar Q, et al. (2003) Public health surveillance of diabetes in the United States. J Public Health Manag Pract Suppl:S44–S51.

    Google Scholar 

  38. Despres JP. (2001) Increasing high density lipoprotein cholesterol, an update on fenofibrate. Am J Cardiol 88(Suppl):30N–36N.

    Article  PubMed  CAS  Google Scholar 

  39. Despres JP. (1998) The insulin resistance-dyslipidemic syndrome of visceral obesity: effect on patient’s risk. Obes Res 6:8S–17S.

    PubMed  Google Scholar 

  40. DeStefano F, Ford ES, Newman J, et al. (1993) Risk factors for coronary heart disease mortality among persons with diabetes. Am Epidemil 3:27–34.

    Article  CAS  Google Scholar 

  41. Diabetes Control and Complications Trial Research Group. (1993) The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986.

    Article  Google Scholar 

  42. Diabetes Prevention Research Group. (2002) Reduction in the evidence of type 2 diabetes with life style intervention or metformin. N Engl J Med 346:393–403.

    Article  Google Scholar 

  43. Dunn CJ, Faulds D. (2000) Nateglinide. Drugs 60:607–617.

    Article  PubMed  CAS  Google Scholar 

  44. Dzau VJ. (1998) Mechanism of protective effects of ACE inhibition on coronary artery disease. Eur Heart J 19(Suppl J):12–16.

    Google Scholar 

  45. Elkeles RS, Diamond JR, et al. (1992) Cardiovascular outcomes in type 2 diabetes. Diabetes Care 15:820–825.

    Article  Google Scholar 

  46. Estacio RO, Schrier RW. (1998) Antihypertensive therapy in type 2 diabetics: implications of the appropriate blood pressure control in diabetics (ABCD) trial. Am J Cardiol 82:9R–14R.

    Article  PubMed  CAS  Google Scholar 

  47. European Diabetes Policy Group 1999. (1999) A desktop guide to type 2 diabetes mellitus. Diabet Med 16:716–730.

    Article  Google Scholar 

  48. Evans A, Krentz AJ. (1999) Benefits and risks of transfer from oral agents to insulin in type 2 diabetes mellitus. S Dur Saf 21:7–22.

    Article  CAS  Google Scholar 

  49. Factor SM, Minase T, Sonneblick EH. (1980) Clinical and morphological features of human hypertensive diabetic cardiomyopathy. Am Heart J 99:446–458.

    Article  PubMed  CAS  Google Scholar 

  50. Fava S, Azzopardi J, Muscat HA, Fenech FF. (1993) Factors that influence outcome in diabetic subjects with myocardial infarction. Diabetes Care 16:1615–1618.

    Article  PubMed  CAS  Google Scholar 

  51. Flegal KM, et al. (1998) Overweight and obesity in the United States: prevalence and trends. 1960–1994. Int J Obes Relat Metab Disord 22:39–47.

    Article  PubMed  CAS  Google Scholar 

  52. Fontbonne A, Charles MA, Juhan-Vague I, et al. (1996) The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group. Diabetes Care 19:920–926.

    Article  PubMed  CAS  Google Scholar 

  53. Ford ES, et al. (2002) Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287:356–359.

    Article  PubMed  Google Scholar 

  54. Frick MH, Elo H. (1987) Primary prevention trial with gemfibrozil I middle aged men with dyslipidemia. N Engl J Med 317:1237–1245.

    Article  PubMed  CAS  Google Scholar 

  55. Froelicher V. (2001) Exercise testing in the new millennium. Prim Care 28:1–4.

    PubMed  CAS  Google Scholar 

  56. Fu Y, Deedwania P. (2001) Management of hypertensive patients with diabetes mellitus. Cin Ger 9:22–36.

    Google Scholar 

  57. Galuska DA, Will JC, Serdula MK, Ford ES. (1999) Are health care professionals advising obese patients to lose weight? JAMA 282:1576–1578.

    Article  PubMed  CAS  Google Scholar 

  58. Garg A, Grundy SM. (1990) Nicotinic acid as therapy for dyslipidemia in non-insulin dependent diabetes mellitus. JAMA 264:723–7226.

    Article  PubMed  CAS  Google Scholar 

  59. Giese M, Lackland DT, Egan BM. (2001) The hypertension initiative of South Carolina. Promoting cardiovascular health through better blood pressure control. JSC Med Assoc 97:57–62.

    CAS  Google Scholar 

  60. Ginsberg HN. (1998) Effects of statins on triglyceride metabolism. Am J Cardiol 81:32B–35B.

    Article  PubMed  CAS  Google Scholar 

  61. Ginsberg HS. (2003) Treatment for patients with the metabolic syndrome. Am J Cardiol 91:29E–39E.

    Article  PubMed  CAS  Google Scholar 

  62. Goldberg IJ. (2001) Diabetic dyslipidemia, causes and consequences. J Clin Endocrinol Metab 86:965–971.

    Article  PubMed  CAS  Google Scholar 

  63. Goldberg RB, Mellies MJ, Sacks FM, et al. (1998) Cardiovascular events and their reduction with pravastatin in diabetic and glucose intolerant myocardial infarction survivors with average cholesterol levels: CARE trial. Circulation 98:2513–2519.

    PubMed  CAS  Google Scholar 

  64. Greco P, Eisenberg J. (1993) Changing physicians’ practices. New Engl J Med 329:1271–1273.

    Article  PubMed  CAS  Google Scholar 

  65. Grimble RF. (2002) Inflammatory status and insulin resistance. Curr Opin Clin Nutr Metab Care 5:551–559.

    Article  PubMed  CAS  Google Scholar 

  66. Groop L. (1992) Sulfonylureas in NIDDM. Diabetes Care 15:737–754.

    Article  PubMed  CAS  Google Scholar 

  67. Grundy SM. (1997) Atherogenic dyslipidemia and the metabolic syndrome. Circulation 95:1–4.

    PubMed  CAS  Google Scholar 

  68. Grundy SM. (2001) Coronary plaque as a replacement for age as a risk factor in global risk assessment. Am J Cardiol 88:8E–11E.

    Article  PubMed  CAS  Google Scholar 

  69. Gum P, O’Keefe JJ, Borkon AM, et al. (1997) Bypass surgery versus coronary angioplasty for revascularization of treated diabetic patients. Circulation 96(9 Suppl):II7–II10.

    Google Scholar 

  70. Gustafsson I, Torp-Pedersen C, Kober L, Gustafsson F, Hildebrant P. (1999) Effect of the angiotensin converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction. J Am Coll Cardiol 34:83–89.

    Article  PubMed  CAS  Google Scholar 

  71. Halliwell B, et al. (1989) Free Radicals in Biology and Medicine. 2nd Ed. Oxford: Clarendon.

    Google Scholar 

  72. Harrigan RA, Nathan MS, Beattie P. (2001) Oral Agents for the treatment of type 2 diabetes mellitus: pharmacology, toxicity and treatment. Ann Emerg Med 38:68.

    Article  PubMed  CAS  Google Scholar 

  73. Harris MI. (2001) Racial and ethnic differences in health care access and health outcomes for adults with type 2 diabetes. Diabetes Care 24:454–459.

    Article  PubMed  CAS  Google Scholar 

  74. Hasnain B, Mooradian AD. (2004) Recent trials of antioxidant therapy: what should we be telling our patients? Cleve Clin J Med 71:327–334.

    PubMed  Google Scholar 

  75. Heinemann L. (1999) Hyperglycemia and insulin analogues: is there a reduction in the incidence? J Diabetes Complications 13:105–114.

    Article  PubMed  CAS  Google Scholar 

  76. Hiatt WR. (2001) New treatment options in intermittent claudication. Int J Clin Pract Suppl 119:20–27.

    PubMed  CAS  Google Scholar 

  77. Hooper L, Summerbell CD, Higgins JP, et al. (2004) Reduced or modified dietary fat for preventing cardiovascular disease. Cochrane Database Syst Rev 2:CD002137.

    Google Scholar 

  78. Horton ES, Clinkingbeard C, Gatlin M, et al. (2000) Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 23:1660–1665.

    Article  PubMed  CAS  Google Scholar 

  79. Imanishi M, Yoshioka K, et al. (1997) Glomerular hypertension as one cause of albuminuria caused by angiotensin converting enzyme inhibitor in early diabetic nephropathy. Kidney Int Suppl 63:S198–S200.

    Google Scholar 

  80. Inzucchi SF, Maggs DG, et al. (1998) Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 338:867–872.

    Article  PubMed  CAS  Google Scholar 

  81. Joint National Committee. (1997) The sixth report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Arch Intern Med 157:2413–2446.

    Article  Google Scholar 

  82. Kabadi M, et al. (2003) Efficacy of sulfonylureas with insulin in type 2 diabetes mellitus. The Annals of Pharmacotherapy 37:1572–1576.

    Article  PubMed  CAS  Google Scholar 

  83. Kahn BB. (1996) Glucose transport: pivotal step in insulin action. Diabetes 45:1644–1654.

    Article  PubMed  CAS  Google Scholar 

  84. Kendall DM, Harmel AP. (2002) The metabolic syndrome, type 2 diabetes, and cardiovascular disease: understanding the role of insulin resistance. Am J Manag Care 8(20 Suppl):S635–653.

    PubMed  Google Scholar 

  85. Kirpichnikov D, et al. (2002) Metformin, an update. Ann Intern Med 137:25–33.

    PubMed  CAS  Google Scholar 

  86. Knobl P, Schernthaner G, et al. (1994) Hemostatic abnormalities persist despite glycemic improvement by insulin therapy in type 2 diabetics. Thromb Haemost 71:692–697.

    PubMed  CAS  Google Scholar 

  87. Kodama M, et al. (2000) Antiplatelet drugs attenuate progression of carotid intima thickness in subjects with type 2 diabetes. Horm Res 97:239–245.

    CAS  Google Scholar 

  88. Kornowski, R, Mintz GS, et al. (1997) Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. Circulation 95:1366–1369.

    PubMed  CAS  Google Scholar 

  89. Koskinen P, et al. (1992) Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 15:820–825.

    Article  PubMed  CAS  Google Scholar 

  90. Krolewski AS, et al. (1987) Magnitude and determinants of coronary artery disease in juvenile onset, insulin dependent diabetes mellitus. Am J Cardiol 59:750–755.

    Article  PubMed  CAS  Google Scholar 

  91. Kudlacek S, Schernthaner G. (1992) The effect of insulin treatment on HbA1C, body weight and lipids in type-2 diabetic patients with secondary failure to sulfonylureas. Horm Metab Res 24:478–483.

    PubMed  CAS  Google Scholar 

  92. Langtry HD, Markham A. (1999) Fluvastatin, a review of it use in lipid disorders. Drugs 57:583–606.

    Article  PubMed  CAS  Google Scholar 

  93. Larme AC, Pugh JA, et al. (1998) Attitudes of primary care providers toward diabetes: barriers to guideline implementation. Diabetes Care 21:1391–1396.

    Article  PubMed  CAS  Google Scholar 

  94. Lazarus JM, Bourgoignie JJ, et al. (1997) Achievement and safety of a low BP goal in chronic renal disease. Hypertension 29:641–650.

    PubMed  CAS  Google Scholar 

  95. Lenhard MJ, Reeves GD. (2001) Continuous subcutaneous insulin infusions: a comprehensive review of insulin pump therapy. Arch Intern Med 161:2293.

    Article  PubMed  CAS  Google Scholar 

  96. Loh KC, Leow MK. (2003) Current therapeutic strategies for type 2 diabetes mellitus. Ann Acad Med Singapore 31:722–729.

    Google Scholar 

  97. Lopez-Candales A. (2001) Metabolic syndrome X: a comprehensive review of the pathophysiology and recommended therapy. J Med 32:283–300.

    PubMed  CAS  Google Scholar 

  98. Lorber D. (2001) Revised clinical practice recommendations. Practical Diabetology March:36–38.

    Google Scholar 

  99. Lovestam-Adrian M, et al. (2001) Diabetic retinopathy, visual acuity, and medical risk indicators. J Diabetes Complications 15:287–294.

    Article  PubMed  CAS  Google Scholar 

  100. Lyons TJ. (1993) Glycation and oxidation: a role in the pathogenesis of atherosclerosis. Am J Cardiol 71:26B–31B.

    Article  PubMed  CAS  Google Scholar 

  101. Marshall JA, Bessesen DH. (2002) Dietary fat and the development of type 2 diabetes. Diabetes Care 25:620–622.

    Article  PubMed  Google Scholar 

  102. Mattock MB, Morrish NJ, et al. (1992) Prospective study of microalbuminuria as a predictor of mortality in NIDDM. Diabetes 41:736–741.

    Article  PubMed  CAS  Google Scholar 

  103. McGill JB, et al. (1994) Factors responsible for impaired fibrinolysis in obese and diabetic patients. Diabetes 43:104–109.

    Article  PubMed  CAS  Google Scholar 

  104. McKelvie RS, Yusuf S, et al. (1999) Comparison of candesartan, enalapril and their combination in congestive heart failure. Circulation 100:1056–1064.

    PubMed  CAS  Google Scholar 

  105. McKenney J. (2002) Combination therapy for elevated low density lipoprotein cholesterol. The key to coronary artery disease risk reduction. Am J Cardiol 90(Suppl):8K–20K.

    Article  PubMed  CAS  Google Scholar 

  106. Menys VS, Bhatnagar D, et al. (1995) Spontaneous platelet aggregation in whole blood is increased in insulin dependent diabetics. Atherosclerosis 112:115–122.

    Article  PubMed  CAS  Google Scholar 

  107. Miettinen TA, Taskinen MR, et al. (1969) Glucose tolerance and plasma insulin in man during acute and chronic administration of nicotinic acid. Acta Med Scand 186:247–253

    Article  PubMed  CAS  Google Scholar 

  108. Mogensen CE, et al. (2000) Randomized controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 1440–1444.

    Google Scholar 

  109. Morgensen CE. (1998) Natural history of cardiovascular and renal disease in patients with type 2 diabetes: effect of therapeutic interventions and risk modifications. Am J Cardiol 82:4R–8R.

    Article  Google Scholar 

  110. Motz R. (2004) Metformin associated lactic acidosis: fact, fiction or both. CV&R March–April:74–75.

    Google Scholar 

  111. Nash D. (2004) The metabolic syndrome: early clues, effective management. Consultant May:859–864.

    Google Scholar 

  112. Nathan DM, Roussell A, et al. (1988) Glyburide or insulin for metabolic control in noninsulin dependent mellitus: a randomized, double blind study. Ann Intern Med 108:334–340.

    PubMed  CAS  Google Scholar 

  113. New JP, Bilous RW. (2000) Insulin sensitivity in hypertensive type 2 diabetic patients after 1 and 19 days with trandolapril. Diabetes Med 17:134–141.

    Article  CAS  Google Scholar 

  114. Novartis Pharmaceuticals Corp. (2001) Starlix Package Insert. Basel, Switzerland.

    Google Scholar 

  115. Oommen KJ, Mathews S. (1999) Zonisamide: a new antiepileptic drug. Clin Neuropharmacol 22:192–200.

    PubMed  CAS  Google Scholar 

  116. Ordoubadi FF, et al. (1997) Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials. Circulation 96:1152–1156.

    Google Scholar 

  117. Owens DR, Zinman B, et al. (2001) Insulins today and beyond. Lancet 358:739–746.

    Article  PubMed  CAS  Google Scholar 

  118. Palumbo PJ (2001) Glycemic control, mealtime glucose excursions, and diabetic complications in type 2 diabetes mellitus. Mayo Clin Proc 76:609–618.

    Article  PubMed  CAS  Google Scholar 

  119. Pan X, Li G, Hu Y, et al. (1997) Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: The Da Qing IGT and Diabetes Study. Diabetes Care 20:537–544.

    Article  PubMed  CAS  Google Scholar 

  120. Parving HH, Lehnert H, et al. (2001) The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870–878.

    Article  PubMed  CAS  Google Scholar 

  121. Petrella RJ, Koval JJ, Cunningham DA, Paterson DH. (2003) Can primary care doctors prescribe exercise to improve fitness? Am J Prev Med 24:316–322.

    Article  PubMed  Google Scholar 

  122. Potter MB, Vu JD, Croughan-Minihane. (2001) Weight management: what patients want from their primary care physicians. J Fam Pract 50:512–518.

    Google Scholar 

  123. Pyorala K, Pedersen TR, et al. (1997) Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary artery disease. Diabetes Care 20:614–620.

    Article  PubMed  CAS  Google Scholar 

  124. Queale WS, et al. (1997) Glycemic control and sliding scale insulin use in medical inpatients with diabetes mellitus. Arch Intern Med 157:545–552.

    Article  PubMed  CAS  Google Scholar 

  125. Rao AK, et al. (1984) Platelet coagulation activity in diabetes mellitus. Evidence for relationship between platelet coagulant hyperactivity and platelet volume. J Lab Clin Med 103:82–92.

    PubMed  CAS  Google Scholar 

  126. Rao S, et al. (2004) Impaired glucose tolerance and impaired fasting glucose. Amer Fam Phys 69 (No 8).

    Google Scholar 

  127. Reaven GM. (1988) Role of insulin resistance in human disease. Diabetes 37:1595–1607.

    Article  PubMed  CAS  Google Scholar 

  128. Ritz E, Orth SR. (1999) Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 341:1127–1133.

    Article  PubMed  CAS  Google Scholar 

  129. Rossing K, Christensen PK, et al. (2002) Dual blockade of the renin-angiotensin system in diabetic retinopathy. Diabetes Care 25:95–100.

    Article  PubMed  CAS  Google Scholar 

  130. Rotbaltt M, et al. (2001) Evidence Based Herbal Medicine. Philadelphia: Hanley & Belfus.

    Google Scholar 

  131. Rubins HB, et al. (1999) Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol: VA-HIT Study group. N Engl J Med 341:410–418.

    Article  PubMed  CAS  Google Scholar 

  132. Samaha FF, et al. (2003) A low carbohydrate diet as compared with a low fat diet in severe obesity. N Engl J Med 348:2074–2081.

    Article  PubMed  CAS  Google Scholar 

  133. Saudek CD, et al. (1996) Implantable insulin pump v. multiple dose insulin for non insulin dependent diabetes mellitus; a randomized clinical trial. JAMA 276:1322–1327.

    Article  PubMed  CAS  Google Scholar 

  134. Schneider SH, Amorosa LF, Khachaduria AK, et al. (1984) Studies on the mechanism of improved glucose control during regular exercise in type 2 diabetes. Diabetologia 26:355–360.

    Article  PubMed  CAS  Google Scholar 

  135. She P, Froelicher VF. (1998) EXTRA: an expert system for exercise test reporting. J Non-Invasive Testing II-4:21–27.

    Google Scholar 

  136. Sherwin RS, et al. (2002) The prevention or delay of type 2 diabetes. Diabetes Care 25:743.

    Google Scholar 

  137. Sinha R, et al. (2002) Prevalence of impaired glucose intolerance among children and adolescents with marked obesity. N Engl J Med 346:802–810.

    Article  PubMed  CAS  Google Scholar 

  138. Sniderman A, Michel C, et al. (1992) Heart disease in patients with diabetes mellitus. J Clin Epidemiol 45:1357–1370.

    Article  PubMed  CAS  Google Scholar 

  139. Sobel BE. (2001) Acceleration of restenosis by diabetes. Circulation 103:1185–1187.

    PubMed  CAS  Google Scholar 

  140. Soler NG, Bennett MA, et al. (1975) Myocardial infarction in diabetics. Q J Med 44:125–132.

    PubMed  CAS  Google Scholar 

  141. Sowers JR, Lester MA. (1999) Diabetes and cardiovascular disease. Diabetes Care 22(Suppl 3):C14–C20.

    PubMed  Google Scholar 

  142. Staessen JA, Fagard R, et al. (1997) Randomized double blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 350:757–764.

    Article  PubMed  CAS  Google Scholar 

  143. Stratton IM, Adler AI, et al. (2000) Association of glycemia with macrovascular and microvascular complications of type 2 diabetes: prospective observational study. BMJ 321:405–412.

    Article  PubMed  CAS  Google Scholar 

  144. Superko HR, Krauss. (1992) Differential effects of nicotinic acid in subjects with different LDL subclass patterns. Atherosclerosis 95:69–76.

    Article  PubMed  CAS  Google Scholar 

  145. Torlone E, Britta M, Rambotti AM, et al. (1993) Improved insulin action and glycemic control after long term angiotensin-converting enzyme induction in subjects with arterial hypertension and type 2 diabetes. Diabetes Care 16:1347–1355.

    Article  PubMed  CAS  Google Scholar 

  146. Tuomilehto J, et al. (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343–1350.

    Article  PubMed  CAS  Google Scholar 

  147. Turner RC. (1999) Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes: progressive requirement for multiple therapies. JAMA 281:2005–2012.

    Article  PubMed  CAS  Google Scholar 

  148. UK Prospective Diabetes Study (UKPDS) Group. (1998) Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 352:837–853.

    Article  Google Scholar 

  149. UK Prospective Diabetes Study (UKPDS) Group. (1998) Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet 352:854–865.

    Article  Google Scholar 

  150. Unger J. (2003) Targeting glycemic control in the primary care setting. The Female Patient 28:12–16.

    Google Scholar 

  151. Unger T. (2000) Neurohormonal modulation in cardiovascular disease. Am Heart J 139:S2–S8.

    Article  PubMed  CAS  Google Scholar 

  152. Vague J, et al. (1980) Obesity and diabetes. Acta Diabetol Lat 17:87–99.

    Article  PubMed  CAS  Google Scholar 

  153. Valmadred CT, et al. (2000) The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria with older onset diabetes mellitus. Arch Intern Med 160:1093–1099.

    Article  Google Scholar 

  154. Van den Berghe G, Wouters P, et al. (2001) Intensive insulin therapy in critically ill patients. N Engl J Med 345:1359–1367.

    Article  PubMed  Google Scholar 

  155. Van Hoeven KH, et al. (1990) A comparison of the pathological spectrum of hypertensive, diabetic and hypertensive diabetic heart disease. Circulation 82:848–855.

    PubMed  Google Scholar 

  156. Wagner E, Austin B, Von Korff M. (1996) Improving outcomes in chronic illness. Manag Care Q 4:12–25.

    PubMed  CAS  Google Scholar 

  157. Wasserman DH, Zinman B. (1994) Exercise in individuals with IDDM (technical review). Diabetes Care 17:924–937.

    PubMed  CAS  Google Scholar 

  158. Weber P, et al. (1997) Vitamin E and human health: rationale for determining recommended intake levels. Nutrition 13:450–460.

    Article  PubMed  CAS  Google Scholar 

  159. Williamson DF, Thompson TJ, Thun M, et al. (2000) Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 23:1499–1504.

    Article  PubMed  CAS  Google Scholar 

  160. Yanovski SZ, et al. (2002) Obesity. N Engl J Med 346:591–602.

    Article  PubMed  CAS  Google Scholar 

  161. Yki-Jarvinen H, Ryysy L, Nikkila K, et al. (1999) Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 130:389–396.

    PubMed  CAS  Google Scholar 

  162. Ziegler D, et al. (1997) Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. Diabetes Care 20:369–373.

    Article  PubMed  CAS  Google Scholar 

  163. Zucchelli P, Zuccala A, et al. (1995) Comparison of the effects of ACE inhibitors and calcium channel blockers on the progression of renal failure. Nephrol Dial Transplan 10(Suppl 9):46–51.

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

(2005). Risk Reduction in Patients With Diabetes. In: Type 2 Diabetes, Pre-Diabetes, and the Metabolic Syndrome. Current Clinical Practice. Humana Press. https://doi.org/10.1385/1-59259-932-X:205

Download citation

  • DOI: https://doi.org/10.1385/1-59259-932-X:205

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-471-5

  • Online ISBN: 978-1-59259-932-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation